Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, announced that it will have two poster presentations at the 2014 American Association for Cancer Research (AACR) Annual Meeting. The conference will take place in San Diego, California, on April 5-9, 2014 at the San Diego Convention Centre. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) shares after opening at $1.28 moved to $1.29 on last trade day and at the end of the day closed at $1.24. Company price to cash ratio as 14.59. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) showed a positive weekly performance of 7.83%.
Arena Pharmaceuticals (NASDAQ:ARNA) SVP William Shanahan, Jr. sold 60,000 shares of the stock on the open market in a transaction that occurred on Tuesday, April 1st. The stock was sold at an average price of $6.37, for a total transaction of $382,200.00. Following the sale, the senior vice president now directly owns 35,000 shares in the company, valued at approximately $222,950. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) shares fell -3.75% in last trading session and ended the day on $6.42. ARNA return on equity ratio is recorded as -19.10% and its return on assets is -6.80%. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) yearly performance is -22.65%.
Exact Sciences Corp. (NASDAQ:EXAS) a Madison company that is developing a DNA-based, noninvasive colon cancer test, plans to sell $125 million worth of shares to the public. EXACT Sciences Corporation (NASDAQ:EXAS) shares moved down -9.33% in last trading session and was closed at $12.92, while trading in range of $12.89 – $13.74. EXACT Sciences Corporation (NASDAQ:EXAS) year to date (YTD) performance is 9.96%.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) on Apr. 2 announced the appointment of Hugh M. Cole to the position of senior vice president and chief business officer. Mr. Cole will be responsible for global business and corporate development, licensing and strategic planning. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) weekly performance is 2.24%. On last trading day company shares ended up $7.77. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) distance from 50-day simple moving average (SMA50) is -3.74%. Analysts mean target price for the company is $8.84.
Leave a Reply